What has happened to bngo stock?
Aug 05, 2021 · BNGO stock is falling despite increased revenue in second-quarter 2021 as compared to the same prior-year quarter. However, one thing is to note that its earnings surprise is -20% and quarterly loss is above the Zacks Consensus Estimate. The stock is progressing with time and continuing to conduct clinical studies which is a good sign.
Is BioNano genomics (bngo) stock breaking down?
Feb 25, 2021 · Revenue was down 38.5% for the quarter, and down 38% over the first three quarters of the year. BNGO stock was trading in the 57 …
How much did Binance (bngo) raise in its IPO?
Bionano (BNGO) is a life sciences company looking to make an impact in the cytogenetics space – that is in the study of chromosomes. This it is planning to …
Why is BioNano (bngo) popping?
Jul 16, 2021 · Shares of Bionano Genomics (NASDAQ: BNGO) were down 13.5% for the week as of the market close on Thursday. Invitae (NYSE: NVTA) stock was off by 12% over the last four days, while Opko Health ...
Is BNGO a good investment?
Is BNGO expected to rise?
The 3 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 8.00, with a high estimate of 12.00 and a low estimate of 6.00. The median estimate represents a +469.40% increase from the last price of 1.41.
Is BNGO a buy or sell?
Is BNGO a US stock?
Who owns Bionano genomics?
Is BNGO a pump and dump?
Is Bionano genomics FDA approved?
What is a good price to buy BNGO?
| Low | Average | High |
|---|---|---|
| $7.00 | $7.00 | $7.00 |
What type of stock is BNGO?
Is BNGO in Russell?
What is the short interest in BNGO?
What does Bionano genomics?
The Reddit Effect Strikes Again
Bottom Line on BNGO Stock
One of the big news stories of 2021 has been the Reddit effect. Retail investors have been using the platform to drive up the prices of many stocks that were previously struggling and attracting short-sellers.
Who is the CEO of Bionano?
BioNano doesn’t get the degree of analyst coverage that headline-grabbing biotech companies have over the past year. CNN Money is following just four investment analysts that cover BNGO stock.
Is Bionano stock undervalued?
Leading the call today is Dr. Erik Holmlin, CEO of Bionano. Such forward-looking statements are based upon current expectations, and there can be no assurances that the results contemplated in these statements will be realized.
Is Bionano Genomics a company?
But unlike most other meme names, Bionano has a highly disruptive product, and its shares are tremendously undervalued. BNGO stock is down 20.8% in the past month.
What is BNGO in 2021?
Shares of genome analysis company Bionano Genomics, Inc. (BNGO) jumped 4.9% on Tuesday and closed at $5.40 in extended trade after the company announced that it signed a definitive agreement to acquire BioDiscovery, Inc., a genomics data-focused software company, for $100 million. The consideration will be paid in a combination of equity and cash. Bionano Genomics’ position in the market, as one of the foremost players in digital cytogenetics and comprehensive genome analysis, is expected to fur
Who is the CEO of Bionano?
SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr® system and the leading software for genomic data visualization, interpretation and reporting, today announced the publication of a study by Johns Hopkins University in the Journal of Clinical & Anatomic Pathology outlining a stepwise approach to adoption of OGM for cancer analysis in the cytogenetics lab. “This publication is by an outstanding team at John
Is Bionano stock undervalued?
Leading the call today is Dr. Erik Holmlin, CEO of Bionano. Such forward-looking statements are based upon current expectations, and there can be no assurances that the results contemplated in these statements will be realized.
Is Bionano a loss?
But unlike most other meme names, Bionano has a highly disruptive product, and its shares are tremendously undervalued. BNGO stock is down 20.8% in the past month.
What is the BNGO symbol?
Bionano (BNGO) might have reported a wider loss than expected in Q3, but that factor is of less importance to Oppenheimer’s Kevin DeGeeter. The life sciences company reported a net loss of $20.75 million, a 92% increase on the same period last year. However, DeGeeter believes the company surpassed expectations on the three most important metrics. First off, for the 6th consecutive quarter, Bionano posted a beat on the top-line, with revenue increasing by 112% year-over-year to $4.7 million vs. t
How much does Bionano generate?
Bionano Genomics trades on the NASDAQ under the ticker symbol "BNGO."
What is Bionano Genomics?
Bionano Genomics has a market capitalization of $1.72 billion and generates $8.50 million in revenue each year . The company earns $-41,110,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.
What is the P/E ratio of Bionano?
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.
Is Bionano Genomics a buy?
The P/E ratio of Bionano Genomics is -20.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Does Bionano pay dividends?
Bionano Genomics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Bionano Grows Revenue From a Small Base
Bionano Genomics does not currently pay a dividend.
Much More Work to Be Done
Bionano announced its third-quarter results on Nov. 4. Revenue shot up 112% to $4.7 million, from $2.2 million a year ago, beating Wall Street’s expectations for the sixth consecutive quarter. While the company delivered triple-digit percentage growth, keep in mind that the baseline revenue number was still very small.
The Bottom Line on BNGO Stock
What a lot of people don’t realize is that science is only half the equation for building a successful medtech business. Adoption of new technology in the medical field can be slow. It often takes a strong sales team to convince doctors to try something new.
